| Identification | Back Directory | [Name]
2-butyl-3-{[2'-(2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride | [CAS]
329055-23-4 | [Synonyms]
Irbesartan HCl
Irbesartan hydrochloride
2-butyl-3-{[2'-(2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride | [EINECS(EC#)]
692-730-7 | [Molecular Formula]
C25H29ClN6O | [MOL File]
329055-23-4.mol | [Molecular Weight]
465 |
| Hazard Information | Back Directory | [Uses]
Irbesartan (SR-47436) hydrochloride is an orally active Ang II type 1 (AT1) receptor blocker (ARB). Irbesartan hydrochloride can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan hydrochloride can be used for the research of high blood pressure, heart failure, and diabetic kidney disease[1]. | [in vivo]
Irbesartan hydrochloride (oral gavage; 50 mg/kg/d; once daily) reduces Th22 lymphocytosis and serum IL-22 level in Ang II-infused mice[1].
Irbesartan hydrochloride (oral gavage; 50 mg/kg/d; once daily) exerts obvious renoprotective effects[1].
Irbesartan hydrochloride (oral gavage; 50 mg/kg/d; once daily) relieves systemic inflammation and renal fibrosis in hypertension mice induced by Ang II[1].
Irbesartan hydrochloride (20 μM; for 3 h) can attenuate Th22 cells recruitment and IL-22 secretion, which might be through inhibiting chemotaxis in hypertensive renal injury mice[1]. | Animal Model: | C57BL/6 mice[1] | | Dosage: | 50 mg/kg | | Administration: | oral gavage; 50 mg/kg/d; once daily | | Result: | Displayed low Th22 cells and IL-22, exerted similar inhibitory effect on Th1 cell proportion and displayed decreased IL-22 level in kidney.
Prevented BP elevation markedly and decreased urinary albumin/creatinine ratio, BUN and Scr.
Repressed the expression of IL-1β, IL-6, TNF-α, α-SMA, FN and Col I and diminished the extent of fibrosis.
|
| Animal Model: | C57BL/6 mice[1] | | Dosage: | 20 μM | | Administration: | 20 μM; for 3 h | | Result: | Downregulated renal CCL20, CCL22 and CCL27 concentrations. |
| [References]
[1] Yong Zhong, et al. Irbesartan may relieve renal injury by suppressing Th22 cells chemotaxis and infiltration in Ang II-induced hypertension. Int Immunopharmacol DOI:10.1016/j.intimp.2020.106789 |
|
|